Company
EpiBiologics
Advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins
- Status
- Operatingas of 2026-09-23
- Business model
- B2B
- Legal name
- EpiBiologics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Our EpiTAC platform leverages a novel atlas of 270+ degradation-inducing protein receptors expressed on the surface of distinct tissue and cell types to create tissue-selective therapies against membrane and extracellular proteins.
Funding snapshot
- Total raised
- $157MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series B, $107M2026-01-08
Funding rounds
- Series B
- $107M2026-01-08, Company stated
- Series A
- 2023-07-20
- Series A
- $50M2023-03-22, Company stated
- Round, 2022
- $73M2022-03-21, SEC form D sold, 15 investors
Loading relationship preview